Crisaborole is a non-steroidal boron-containing topical phosphodiesterase-4 inhibitor that has been approved by the US FDA for the treatment of atopic dermatitis in children (>3 months of age) and adults. Of late, its efficacy has been outlined in the treatment of many other dermatoses, including vitiligo, psoriasis, morphea, seborrheic dermatitis, stasis dermatitis and vulvar leucoplakia, to name a few. While crisaborole represents a valuable non-steroidal alternative in dermatological therapy, the primary limitation is its high cost compared to other topical agents. Nevertheless, despite this limitation, its use in recalcitrant cases can be worth considering.